Beyond Cholesterol: Why ApoB May Be a Better Indicator of Stroke Risk
Regular cholesterol checks are a standard part of preventative healthcare, but emerging evidence suggests that focusing solely on LDL cholesterol (“bad” cholesterol) may not provide a complete picture of your stroke risk. Cardiologists are increasingly emphasizing the importance of Apolipoprotein B (ApoB) as a more revealing indicator of arterial health and potential stroke risk.
The Limitations of Traditional Cholesterol Testing
Traditional lipid testing, while valuable, has limitations. It doesn’t necessarily reflect the true danger posed by particles circulating in the bloodstream. A person can have a seemingly normal cholesterol level but still harbor numerous small, dense particles that silently accumulate and increase the risk of arterial blockage – a risk that standard cholesterol tests might miss.
Understanding Apolipoprotein B (ApoB)
Apolipoprotein B is a protein found on all cholesterol-carrying particles that have the potential to block arteries. According to cardiologists, ApoB is a superior marker for assessing stroke risk since it measures the total number of potentially harmful particles, rather than just the amount of cholesterol they carry. Where cholesterol measures the “amount” of fat, ApoB measures the number of dangerous “projectiles” ready to affect your vessels. Parade
When to Ask Your Doctor About ApoB Testing
ApoB is not yet part of the standard lipid profile, which typically includes total cholesterol, HDL, LDL, and triglycerides. However, you can request an ApoB test from your doctor, particularly if your LDL cholesterol level is borderline (between 1.3 and 1.6 g/L) or if you have a complex metabolic profile, such as diabetes, abdominal obesity, or high triglycerides. ApoB testing is too recommended for individuals with a family history of early cardiovascular events despite normal cholesterol levels.
What’s Considered a Normal ApoB Level?
A healthy individual generally has an ApoB level below 90 mg/dL. While a slightly higher result isn’t necessarily cause for alarm, it shouldn’t be ignored. Simple lifestyle adjustments, such as increasing fiber intake, reducing ultra-processed carbohydrates, and engaging in regular physical activity, can facilitate lower ApoB levels.
Beyond ApoB: Other Important Factors for Stroke Prevention
Cardiologists emphasize that ApoB should be considered alongside other crucial health metrics. Maintaining healthy blood pressure (ideally below 120/80 mmHg) is vital, as hypertension directly weakens cerebral arteries. Addressing sleep disorders, such as obstructive sleep apnea, and monitoring underlying conditions like atrial fibrillation or certain blood disorders are also critical for comprehensive stroke risk assessment. Verywell Health
The Link Between Cholesterol and Stroke
High cholesterol, specifically LDL cholesterol, contributes to the buildup of plaque in arteries (atherosclerosis). This plaque can narrow arteries, reducing blood flow to the brain and increasing the risk of ischemic stroke. Lowering LDL cholesterol through lifestyle changes and, when necessary, medication, remains an important strategy for stroke prevention. Johns Hopkins Public Health
Recent Research on LDL-C Lowering
Concerns about potential cognitive issues or stroke risk associated with very low LDL-C levels have been largely refuted by recent studies. Research has not demonstrated an increased risk of cognitive impairment, Alzheimer’s dementia, or hemorrhagic stroke with LDL-C lowering therapies. American College of Cardiology
Related reading
- Hospital COVID-19 Protocols: Remdesivir and Ventilator Deaths Examined
- Genencell Pushes Ahead with Shingles Trial Despite Animal Test Safety Issues
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)